Takeda Moves Out From Licensing Agreement With Theravance Biopharma
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE:TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties' collaboration agreement with Theravance Biopharma Inc (NASDAQ:TBPH).
在其第一季度財報中， 武田製藥 Co Ltd (NYSE: TAK) 表示，它同意停止進一步開發治療術後胃腸道功能障礙的 TAK-954，並同意雙方與之達成合作協議 Theravance 生物製藥公司 （納斯達克：TBPH）。
Takeda has discontinued 13 clinical-stage programs and discovery and pre-clinical efforts in adeno-associated virus (AAV) gene therapy.
武田已經停止了腺相關病毒 (AAV) 基因療法的13個臨床階段項目、發現和臨床前工作。
Also Read: Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues.
另請閱讀：武田的22財年淨利潤增長了38％，但預計23財年收入將下降。
The companies entered into the agreement in June 2016, in which Theravance Biopharma received an upfront cash payment of $15 million and was eligible to receive $110 million in milestone payments.
兩家公司於2016年6月簽訂協議，根據該協議，Theravance Biopharma獲得了1500萬美元的預付現金，並有資格獲得1.1億美元的里程碑式付款。
The investigational drug did not meet its endpoints in the Phase 2b study.
在2b期研究中，該研究藥物未達到其終點。
Takeda also cut sibofimloc, a small molecule for Crohn's disease (post-operative and ileal-dominant), after the Phase 2a study did not meet its endpoints.
在2a期研究未達到終點之後，武田還切斷了治療克羅恩病（術後和迴腸顯性）的小分子sibofimloc。
From Phase 3, Takeda cut trials on four drugs already approved in other indications, namely the cancer drugs Ninlaro (ixazomib), Zejula (Niraparib), antiviral Livtencity (maribavir)and Takhzyro (lanadelumab), a hereditary angioedema drug.
從第三階段開始，武田削減了對四種已經批准用於其他適應症的藥物的試驗，即抗癌藥物Ninlaro（ixazomib）、Zejula（Niraparib）、抗病毒藥物Livtencity（maribavir）和遺傳性血管性水腫藥物Takhzyro（lanadelumab）。
Price Action: TAK shares are down 5.15% at $16.11, and TBPH shares are down 4.27% at $10.98 on the last check Thursday.
價格走勢： 在週四的最後一張支票中，TAK股價下跌5.15％，至16.11美元，TBPH股價下跌4.27％，至10.98美元。